Clinical Trial Update: SOLIACS: Solian Solution in the Acute Setting [Phase 4]

View source ↗

Summary

Phase 4 trial SOLIACS evaluated Solian (amisulpride) solution in the acute setting for schizophrenia. The study, conducted by Sanofi, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Solian (amisulpride)

Snippet

Sponsor: Sanofi | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED